Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting

COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
September 23, 2019 10:01 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...
July 31, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office

COLUMBUS, Ohio, July 31, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
June 03, 2019 10:43 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and...
May 28, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene

COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
May 07, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting

COLUMBUS, Ohio, May 07, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology...
April 23, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

COLUMBUS, Ohio, April 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
March 11, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
March 04, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
December 10, 2018 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

COLUMBUS, Ohio, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...